论文部分内容阅读
目的：观察脂必妥对脑梗死病人血脂及载脂蛋白的影响。方法：脂必妥组３０例（男性１９例，女性１１例；年龄６４±ｓ４ａ）给脂必妥１．０５ｇ，ｐｏ，ｔｉｄ；对照组３０例（男性２０例，女性１０例；年龄６１±５ａ）给烟酸肌醇酯０．４ｇ，ｐｏ，ｔｉｄ；疗程均为１ｍｏ。结果：２组均有显著降低ＴＧ，ＴＣ作用，脂必妥组有显著的降低低密度脂蛋白胆固醇（ＬＤＬ－ｃｈ）及载脂蛋白Ｂ１００（ＡｐｏＢ１００）的作用（Ｐ＜０．０５）及升高高密度脂蛋白及载脂蛋白ＡＩ（ＡｐｏＡＩ）作用，而对照组无上述作用；故ＡｐｏＡＩ／ＡｐｏＢ１００比值脂必妥组显著高于对照组（Ｐ＜０．０５），不良反应见于对照组。结论：脂必妥是较好的降脂药物。
Objective: To observe the effect of Lipid on blood lipids and apolipoprotein in patients with cerebral infarction. Methods: Lipostatin group of 30 patients (19 males, 11 females; age 64 ± s4a) given liposide 1.05g, po, tid; control group of 30 patients (20 males and 10 females; age 61 ± 5a) To nicotinic acid inositol 0.4g, po, tid; course of treatment were 1mo. Results: The TG and TC effects were significantly reduced in both groups. The effects of low density lipoprotein cholesterol (LDL-ch) and apolipoprotein B100 (ApoB100) (P <0.05) and l High-density lipoprotein and apolipoprotein AI (ApoAI), while the control group did not have the above-mentioned effects. Therefore, the ratio of ApoAI / ApoB100 in the lipid profile was significantly higher than that in the control group (P <0.05). Adverse reactions were found in the control group. Conclusion: Lipid is a good lipid-lowering drug.